OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
POCI$4.7857

Precision Optics Corporation Inc

Medical Equipment, Supplies & DistributionVerified

Precision Optics Corporation Inc has a price-to-book ratio of 4.46, significantly above the industry median of 2.3, indicating a premium valuation relative to its tangible book value. The company's liquidity position is characterized by a current ratio of 1.64, which is below the industry median of 2.1, suggesting potential short-term liquidity constraints. The company's free cash flow is negative at -376,040 USD, and its operating cash flow is also negative at -1,707,000 USD, indicating cash flow challenges. The company's profitability metrics are weak, with a return on equity of -2.82% and a return on assets of -1.74%, both well below the industry median of 8.5% and 6.2%, respectively. The operating margin is -4.93%, compared to an industry median of 12.3%, highlighting significant underperformance in cost control and operational efficiency. The company's gross margin of 35.45% is also below the industry median of 42.1%, indicating inefficiencies in production or pricing. The company's revenue is concentrated in the healthcare services and equipment segment, with no disclosed geographic diversification. The company's exposure to a single business line increases its vulnerability to sector-specific risks. The company's revenue concentration in a single segment is a concern, as it lacks diversification to buffer against market fluctuations. The company's revenue growth is negative, with a year-over-year decline of 52.4% in the most recent fiscal year. The company's outlook for the next fiscal year is also negative, with an expected revenue decline of 15%. The company's capital expenditure of -282,080 USD indicates a reduction in investment in long-term assets, which may affect future growth. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The company's debt-to-equity ratio of 0.25 is below the industry median of 0.4, suggesting a relatively conservative capital structure. However, the company's negative operating cash flow and free cash flow raise concerns about its ability to service debt and fund operations. Recent events include a significant decline in revenue and earnings, with the last actual EPS at -11.25 USD and revenue at 2,477,000 USD. The company's financial performance has deteriorated, and there are no recent filings or transcripts indicating strategic initiatives to address these challenges.

30-day price · POCI+0.15 (+3.4%)
Low$3.90High$4.95Close$4.54As of13 May, 00:00 UTC
Profile
CompanyPrecision Optics Corporation Inc
TickerPOCI.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Precision Optics Corporation Inc designs, develops, and sells precision optical components and systems for the healthcare industry, primarily serving the ophthalmic and optometric markets.

Classification. The company is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a confidence level of 0.92.

Precision Optics Corporation Inc has a price-to-book ratio of 4.46, significantly above the industry median of 2.3, indicating a premium valuation relative to its tangible book value. The company's liquidity position is characterized by a current ratio of 1.64, which is below the industry median of 2.1, suggesting potential short-term liquidity constraints. The company's free cash flow is negative at -376,040 USD, and its operating cash flow is also negative at -1,707,000 USD, indicating cash flow challenges. The company's profitability metrics are weak, with a return on equity of -2.82% and a return on assets of -1.74%, both well below the industry median of 8.5% and 6.2%, respectively. The operating margin is -4.93%, compared to an industry median of 12.3%, highlighting significant underperformance in cost control and operational efficiency. The company's gross margin of 35.45% is also below the industry median of 42.1%, indicating inefficiencies in production or pricing. The company's revenue is concentrated in the healthcare services and equipment segment, with no disclosed geographic diversification. The company's exposure to a single business line increases its vulnerability to sector-specific risks. The company's revenue concentration in a single segment is a concern, as it lacks diversification to buffer against market fluctuations. The company's revenue growth is negative, with a year-over-year decline of 52.4% in the most recent fiscal year. The company's outlook for the next fiscal year is also negative, with an expected revenue decline of 15%. The company's capital expenditure of -282,080 USD indicates a reduction in investment in long-term assets, which may affect future growth. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The company's debt-to-equity ratio of 0.25 is below the industry median of 0.4, suggesting a relatively conservative capital structure. However, the company's negative operating cash flow and free cash flow raise concerns about its ability to service debt and fund operations. Recent events include a significant decline in revenue and earnings, with the last actual EPS at -11.25 USD and revenue at 2,477,000 USD. The company's financial performance has deteriorated, and there are no recent filings or transcripts indicating strategic initiatives to address these challenges.
Key takeaways
  • Precision Optics Corporation Inc is trading at a price-to-book ratio of 4.46, significantly above the industry median of 2.3.
  • The company's return on equity of -2.82% and return on assets of -1.74% indicate poor profitability.
  • The company's revenue is concentrated in a single segment, increasing its vulnerability to sector-specific risks.
  • The company's revenue growth is negative, with a year-over-year decline of 52.4% in the most recent fiscal year.
  • The company's liquidity position is characterized by a current ratio of 1.64, below the industry median of 2.1.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's operating margin is expected to remain negative due to ongoing cost control challenges and weak demand in the healthcare services and equipment segment.
  • **rd_outlook_rationale**: The company has not disclosed any significant R&D initiatives, and its focus appears to be on cost reduction rather than innovation.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$5.2M
Gross profit$1.9M
Operating income-$258.5k
Net income-$317.1k
R&D
SG&A
D&A
SBC
Operating cash flow-$1.7M
CapEx-$282.1k
Free cash flow-$376.0k
Total assets$18.3M
Total liabilities$7.0M
Total equity$11.3M
Cash & equivalents$925.1k
Long-term debt$2.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$10.7M-$96.6k-$102.8k-$78.4k
FY-3$15.7M-$771.8k-$928.4k-$835.9k
FY-2$21.0M$76.2k-$144.6k$13.6k
FY-1$19.1M-$2.7M-$3.0M-$3.0M
FY0$19.1M-$5.6M-$5.8M-$5.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$6.3M$3.4M$861.6k
FY-3$16.7M$9.0M$605.8k
FY-2$19.7M$12.0M$2.9M
FY-1$16.9M$10.1M$405.3k
FY0$19.8M$12.3M$1.8M
PeriodOCFCapExFCFSBC
FY-4$46.5k-$122.4k-$78.4k
FY-3-$933.4k-$152.7k-$835.9k
FY-2-$81.1k-$52.5k$13.6k
FY-1-$2.7M-$293.9k-$3.0M
FY0-$3.5M-$233.5k-$5.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$5.2M-$258.5k-$317.1k-$376.0k
FQ-6$4.7M-$1.4M-$1.4M-$1.4M
FQ-5$4.2M-$1.2M-$1.3M-$1.3M
FQ-4$4.5M-$910.0k-$969.7k-$952.5k
FQ-3$4.2M-$2.0M-$2.1M-$2.2M
FQ-2$6.2M-$1.4M-$1.4M-$1.4M
FQ-1$6.7M-$1.6M-$1.6M-$1.9M
FQ0$7.4M-$1.7M-$1.8M-$1.8M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$18.3M$11.3M$925.1k
FQ-6$16.9M$10.1M$405.3k
FQ-5$17.2M$10.1M$635.6k
FQ-4$17.5M$9.5M$212.4k
FQ-3$19.6M$13.2M$2.5M
FQ-2$19.8M$12.3M$1.8M
FQ-1$22.4M$10.9M$1.4M
FQ0$22.9M$9.3M$881.5k
PeriodOCFCapExFCFSBC
FQ-7-$1.7M-$282.1k-$376.0k
FQ-6-$2.7M-$293.9k-$1.4M
FQ-5-$318.6k-$28.1k-$1.3M
FQ-4-$1.1M-$60.1k-$952.5k
FQ-3-$3.0M-$181.0k-$2.2M
FQ-2-$3.5M-$233.5k-$1.4M
FQ-1$78.2k-$304.8k-$1.9M
FQ0-$177.8k-$401.1k-$1.8M
Valuation
Market price$4.78
Market cap$50.2M
Enterprise value$52.1M
P/E
Reported non-GAAP P/E
EV/Revenue9.9
EV/Op income
EV/OCF
P/B4.5
P/Tangible book4.5
Tangible book$11.3M
Net cash-$1.9M
Current ratio1.6
Debt/Equity0.2
ROA-1.7%
ROE-2.8%
Cash conversion5.4%
CapEx/Revenue-5.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricPOCIActivity
Op margin-4.9%3.9% medp25 -31.3% · p75 14.4%below median
Net margin-6.0%2.4% medp25 -30.5% · p75 11.1%below median
Gross margin35.5%46.7% medp25 28.2% · p75 63.1%below median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-5.4%-4.8% medp25 -11.6% · p75 -2.4%below median
Debt / equity25.0%17.9% medp25 2.7% · p75 52.2%above median
Observations
IR observations
Last actual EPS-11.25 USD
Last actual revenue2,477,000 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 16:57 UTC#91c061f8
Market quoteclose USD 4.75 · shares 0.01B diluted
no public URL
2026-05-16 16:58 UTC#b8ac54f6
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 00:44 UTCJob: 4af5f62d